key: cord-0943938-gyv6pev2
authors: Ao, Zhujun; Chan, Mable; Ouyang, Maggie Jing; Abiola, Olukitibi Titus; Mahmoudi, Mona; Kobasa, Darwyn; Yao, Xiaojian
title: Prunella vulgaris extract and suramin block SARS-coronavirus 2 virus Spike protein D614 and G614 variants mediated receptor association and virus entry in cell culture system
date: 2020-08-28
journal: bioRxiv
DOI: 10.1101/2020.08.28.270306
sha: 59bd4e7c483519fa26fa6d626caac0cb41841a80
doc_id: 943938
cord_uid: gyv6pev2

Until now, no approved effective vaccine and antiviral therapeutic are available for treatment or prevention of SARS-coronavirus 2 (SCoV-2) virus infection. In this study, we established a SCoV-2 Spike glycoprotein (SP), including a SP mutant D614G, pseudotyped HIV-1-based vector system and tested their ability to infect ACE2-expressing cells. This study revealed that a C-terminal 17 amino acid deletion in SCoV-2 SP significantly increases the incorporation of SP into the pseudotyped viruses and enhanced its infectivity, which may be helpful in the design of SCoV2-SP-based vaccine strategies. Moreover, based on this system, we have demonstrated that an aqueous extract from the Chinese herb Prunella vulgaris (CHPV) and a compound, suramin, displayed potent inhibitory effects on both wild type and mutant (G614) SCoV-2 SP pseudotyped virus (SCoV-2-SP-PVs)-mediated infection. The 50% inhibitory concentration (IC50) for CHPV and suramin on SCoV-2-SP-PVs are 30, and 40 μg/ml, respectively. To define the mechanisms of their actions, we demonstrated that both CHPV and suramin are able to directly interrupt SCoV-2–SP binding to its receptor ACE2 and block the viral entry step. Importantly, our results also showed that CHPV or suramin can efficiently reduce levels of cytopathic effect caused by SARS-CoV-2 virus (hCoV-19/Canada/ON-VIDO-01/2020) infection in Vero cells. Furthermore, our results demonstrated that the combination of CHPV/suramin with an anti-SARS-CoV-2 neutralizing antibody mediated more potent blocking effect against SCoV2-SP-PVs. Overall, this study provides evidence that CHPV and suramin has anti-SARS-CoV-2 activity and may be developed as a novel antiviral approach against SARS-CoV-2 infection.

The recent and ongoing outbreak of Coronavirus disease 2019 (COVID-19) has antiviral activities [24] , and most of these are generally of low toxicity, cheap and 1 readily accessible. As an easily accessible and low-cost natural source, they are 2 especially valuable as potential new sources for rapid responses against the ongoing 3 COVID-19 pandemic. Prunella vulgaris, widely distributed in China, Europe, 4 northwestern Africa and North America, is known as a self-heal herb and studies 5 have previously found that a water-soluble substance from Chinese Herb Prunella 6 vulgaris (CHPV) exhibit significant antiviral activity against HIV, HSV and Ebola virus Materials and methods 1 Plasmid constructs 2 The SARS-CoV-2 expressing plasmids (pCAGGS-nCoVSP, pCAGGS-nCoVSPΔC 3 and pCAGGS-nCoVSPΔC G614 ) containing SARS-CoV-2 SP transgene (GenBank 4 accession No. MN908947) or corresponding mutated genes for SPΔC and ΔC G614 . 5 The SPΔC and ΔC G614, were generated by mutagenic PCR technique. Primers are that binds to the Spike-ACE2 complex was added followed by applying the 41 HRP-conjugated anti-goat IgG and 3,3',5,5'-tetramethylbenzidine (TMB) substrate.

The intensity of the yellow color is then measured at 450 nm.

Western blot (WB) analyses 1 To detect cellular protein ACE2, SARS-CoV-2-SP, or SPΔC in transfected cells or 2 SCoV-2-SP-VPs, transfected 293T ACE2 cells or VPs were lysed in RIPA buffer, and 3 directly loaded into the 10 % SDS-PAGE gel and the presence of each protein was 4 detected by WB with various corresponding antibodies. 

The SARS-CoV-2 SP including S1/S2 were clearly detected in both To test whether the infection is ACE2-dependent, we infected various cell lines, 39 including HEK293T, 293T ACE2 and VeroE6 with SP-PVs and SPΔC-PVs, respectively.

The results showed that these pseudoviruses were only able to efficiently infect 41 293T ACE2 cells, and not HEK293T or VeroE6 cells ( Fig. 2A) . In parallel, we only 42 detected high level expression of the SARS-CoV-2 receptor ACE2 in 293T ACE2 cells, 43 but not in the 293T or Vero E6 cells (Fig. 2B ).

In addition, we have generated a GFP + SARS-CoV-2-SP-mediated virus entry system activity. Results showed that a strong inhibitory effect was achieved when cells 7 were pretreated with CHPV or Suramin one hour before infection or when the 8 compounds were present simultaneously with SP-PVs ( Fig. 4A and B) . Interestingly, 9 even when drug was added at one hr post-infection, CHPV still exhibited nearly 70% 10 inhibition on SPΔC G614 -PVs infection (Fig. 4A) , while for Suramin, a lower inhibitory 11 effect (about 30% inhibition) was also observed (Fig. 4B) . When CHPV or Suramin 12 was added to culture after 3 hrs of infection, no inhibitory activity on viral infection was 13 observed ( Fig. 4A and B) . These results suggest that both CHPV and suramin act on 

Results revealed that the presence of either CHPV or suramin was able to specifically 21 target and significantly reduce the SARS-CoV2-SP-ACE2 interaction ( Fig. 4C and D) .

It should be noted that the neutralizing antibody (SAD-S35) also showed a strong 23 inhibition on SARS-CoV2-SP/ACE2 interaction ( Fig. 4C and D) . inhibited to 78%, while in the presence of CHPV or suramin alone, inhibition rate was 34 65% or 40% (Fig. 5A) . These results suggest that a combination of these two 35 compounds may be able to achieve more efficient inhibition against SARS-CoV-2 36 infection.

The anti-SARS-CoV-2 neutralizing antibody (SAD-S35) was also tested and showed approximately 25% decrease of infection. However, nearly 80% inhibitory effect was 3 achieved when the same concentration of SAD-S35 was combined with CHPV 4 (25µg/ml), or approximately 60% inhibitory effect was achieved when combined with 5 suramin (25µg/ml), while CHPV or suramin alone only mediated 50% or 38% 6 inhibition, respectively (Fig. 5C ). All together, the results clearly indicate that a 7 combination of CHPV or suramin with SAD-S35 is able to more potently block 8 SARS-CoV2 infection. By including a low dose of nAb, the amounts of CHPV or 9 Suramin needed to achieve highly effective inhibition of SARS-CoV2 infection can be 10 reduced.

Given that both CHPV and suramin are able to block the SARS-CoV2-SP

pseudovirus entry, we next tested whether these two drugs could block wild type 

The results are the mean ± SD of duplicate samples, and the data are representative 

Infected Pneumonia

Temporal estimates of

The cytoplasmic tail of the severe acute respiratory syndrome 1